I am a senior researcher with approximately 20 years of experience in lung cancer research and genetic epidemiology, as well as more recent experience in pharmacogenomics. My work focuses on genome-wide association studies (GWAS) and integrative analyses, such as expression quantitative trait loci, to identify germline variants that influence cancer susceptibility, prognosis, and treatment response, particularly in lung cancer and opioid pharmacogenomics. I have contributed to international consortia investigating the genetic determinants of COVID-19 severity, vaccine response, and long COVID. Through multidisciplinary collaborations with clinicians (including medical oncologists, pneumologists and palliative care experts), computational biologists and bioinformaticians, my research aims to translate genetic insights into predictive biomarkers and personalized therapeutic strategies, advancing precision medicine in oncology and beyond.
Research Activities
Multiomic integration to identify regulatory pathways, gene modules, protein networks, and composite signals associated with pathological phenotypes.
Implementation of studies that combine classical epidemiological methods with high-throughput technologies to reveal the intricate relationship between molecular profiles, environmental exposures, and disease risk.
Exploring the inverse relationship between diseases and comorbidities by means of genetic and clinical data analysis.
Genome-wide association studies (GWAS) in large patient series and cohorts, also using biobank data.
